...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue
【24h】

Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue

机译：难治性狼疮肾炎的生物标志物：肾脏组织的芯片研究。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The prognosis of severe lupus nephritis (LN) is very different among individual patients. None of the current biomarkers can be used to predict the development of refractory LN. Because kidney histology is the gold standard for diagnosing LN, the authors hypothesize that molecular signatures detected in kidney biopsy tissue may have predictive value in determining the therapeutic response. Sixty-seven patients with biopsy-proven severely active LN by International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification III/IV were recruited. Twenty-three kidney tissue samples were used for RNA microarray analysis, while the remaining 44 samples were used for validation by real-time polymerase chain reaction (PCR) gene expression analysis. From hundreds of differential gene expressions in refractory LN, 12 candidates were selected for validation based on gene expression levels as well as relevant functions. The candidate biomarkers were members of the innate immune response molecules, adhesion molecules, calcium-binding receptors, and paracellular tight junction proteins. S100A8, ANXA13, CLDN19 and FAM46B were identified as the best kidney biomarkers for refractory LN, and COL8A1 was identified as the best marker for early loss of kidney function. These new molecular markers can be used to predict refractory LN and may eventually lead to novel molecular targets for therapy.
机译：重度狼疮性肾炎（LN）的预后在各个患者中有很大不同。当前的生物标志物均不能用于预测难治性LN的发展。由于肾脏组织学是诊断LN的金标准，因此作者假设在肾脏活检组织中检测到的分子标记可能在确定治疗反应中具有预测价值。招募了67例经国际肾脏病学会/肾脏病理学会（ISN / RPS）分级为III / IV的活检证实为严重活动性LN的患者。 23个肾脏组织样本用于RNA微阵列分析，而其余44个样本用于通过实时聚合酶链反应（PCR）基因表达分析进行验证。从难治性LN的数百种差异基因表达中，根据基因表达水平和相关功能选择了12种候选基因进行验证。候选生物标志物是先天免疫应答分子，粘附分子，钙结合受体和细胞旁紧密连接蛋白的成员。 S100A8，ANXA13，CLDN19和FAM46B被确定为难治性LN的最佳肾脏生物标志物，COL8A1被确定为早期肾功能丧失的最佳标志物。这些新的分子标记物可用于预测难治性LN，并可能最终导致治疗的新分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号